NVO:NYE-Novo Nordisk A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 127.51

Change

0.00 (0.00)%

Market Cap

USD 609.93B

Volume

9.24M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 1.03B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
CVM CEL-SCI Corp

N/A

USD 0.08B

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 20.43 % 0.00 %

N/A

N/A
THNR Amplify ETF Trust 12.82 % 0.00 %

N/A

N/A
TTTX:CA Global X Innovative Bluec.. 9.79 % 0.00 %

N/A

CAD 3.26M
PPH VanEck Pharmaceutical ETF 9.08 % 0.36 %

N/A

USD 0.75B
PJIO PGIM ETF Trust 7.47 % 0.00 %

N/A

USD 0.01B
BELT BlackRock Long-Term U.S. .. 7.08 % 0.00 %

N/A

N/A
AADR AdvisorShares Dorsey Wrig.. 6.28 % 0.00 %

N/A

USD 0.02B
PJBF 5.53 % 0.00 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

N/A

N/A
FPXI First Trust International.. 4.44 % 0.70 %

N/A

USD 0.15B
PINK Simplify Exchange Traded .. 3.70 % 0.00 %

N/A

USD 0.25B
SPWO SP Funds Trust 3.62 % 0.00 %

N/A

USD 0.01B
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

N/A

N/A
IDVO Amplify International Enh.. 3.09 % 0.00 %

N/A

USD 0.10B
APIE Trust For Professional Ma.. 1.81 % 0.00 %

N/A

USD 0.28B
AVSD American Century ETF Trus.. 1.63 % 0.00 %

N/A

USD 0.15B
HAZ:CA Global X Active Global Di.. 0.00 % 0.94 %

N/A

CAD 0.45B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

N/A

USD 0.78B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

N/A

N/A
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
PTIN Pacer Trendpilot Internat.. 0.00 % 0.00 %

N/A

USD 0.15B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

N/A

USD 0.49B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

N/A

USD 0.70B
LRNZ TrueShares Technology AI .. 0.00 % 0.00 %

N/A

USD 0.03B
LEAD-U:CA 0.00 % 0.00 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 0.00 % 0.00 %

N/A

CAD 4.17M
NTSI WisdomTree International .. 0.00 % 0.00 %

N/A

USD 0.32B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.26% 79% B- 85% B
Dividend Return 1.14% 20% F 27% F
Total Return 24.39% 76% C+ 84% B
Trailing 12 Months  
Capital Gain 39.66% 85% B 86% B+
Dividend Return 1.29% 20% F 18% F
Total Return 40.95% 85% B 85% B
Trailing 5 Years  
Capital Gain 381.44% 100% F 98% N/A
Dividend Return 16.16% 20% F 59% D-
Total Return 397.61% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.98% 88% B+ 93% A
Dividend Return 42.72% 88% B+ 93% A
Total Return 1.73% 20% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 26.32% 82% B 39% F
Risk Adjusted Return 162.31% 100% F 100% F
Market Capitalization 609.93B 100% F 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.